Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominik Berthold

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Journal for Immunotherapy of Cancer|October 31, 2022
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumorsElizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, et al.
Revue Medicale Suisse|February 2, 2022
[2021 Oncology update]May-Lucie Meyer, Konstantina Chrysou, Antonia Stamatiou, et al.
Swiss Medical Weekly|August 20, 2023
Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancerArnoud J Templeton, Aurelius Omlin, Dominik Berthold, et al.
Cancer|April 16, 2015
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancerMatthew D Galsky, Sumanta K Pal, Simon Chowdhury, et al.
Revue Medicale Suisse|January 17, 2024
[Oncology: what's new in 2023]Jeremy Jankovic, Karim Abdelhamid, Dominik Berthold, et al.
Revue Medicale Suisse|January 20, 2023
[Oncology: what's new in 2022]Tu Nguyen-Ngoc, Karim Abdelhamid, Nils Degrauwe, et al.
Critical Reviews in Oncology/Hematology|June 21, 2015
Prostate Cancer Unit Initiative in Europe: A position paper by the European School of OncologyRiccardo Valdagni, Hendrik Van Poppel, Michael Aitchison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2026
Combinatorial delivery of low-dose radiotherapy and immunotherapy to patients with immune-excluded tumors enhances CD8+ T cell functionalityMaria Ochoa-de-Olza, Nicolas Rayroux, Martina Imbimbo, et al.
Lancet (London, England)|April 11, 2022
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial designKarim Fizazi, Stéphanie Foulon, Joan Carles, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Journal for Immunotherapy of Cancer|October 31, 2022
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumorsElizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, et al.
Revue Medicale Suisse|February 2, 2022
[2021 Oncology update]May-Lucie Meyer, Konstantina Chrysou, Antonia Stamatiou, et al.
Swiss Medical Weekly|August 20, 2023
Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancerArnoud J Templeton, Aurelius Omlin, Dominik Berthold, et al.
Cancer|April 16, 2015
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancerMatthew D Galsky, Sumanta K Pal, Simon Chowdhury, et al.
Revue Medicale Suisse|January 17, 2024
[Oncology: what's new in 2023]Jeremy Jankovic, Karim Abdelhamid, Dominik Berthold, et al.
Revue Medicale Suisse|January 20, 2023
[Oncology: what's new in 2022]Tu Nguyen-Ngoc, Karim Abdelhamid, Nils Degrauwe, et al.
Critical Reviews in Oncology/Hematology|June 21, 2015
Prostate Cancer Unit Initiative in Europe: A position paper by the European School of OncologyRiccardo Valdagni, Hendrik Van Poppel, Michael Aitchison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2026
Combinatorial delivery of low-dose radiotherapy and immunotherapy to patients with immune-excluded tumors enhances CD8+ T cell functionalityMaria Ochoa-de-Olza, Nicolas Rayroux, Martina Imbimbo, et al.
Lancet (London, England)|April 11, 2022
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial designKarim Fizazi, Stéphanie Foulon, Joan Carles, et al.
Pageof 4